Prognostic Assessment of the PET-CT Role in Primary Patients with Hodgkin Lymphoma: Do We Still Need More Data?

• Published in: Blood 2018-11, Vol.132 (Supplement 1), p.5350-5350
• Main Authors: Novosad, Olga, Skrypets, Tetiana, Pastushenko, Ian, Gorbach, Oleksandr, Ashykhmin, Andrij, Kmetyuk, Yaroslav, Karpova, Olga, Mykhalska, Larisa, Kindrakevych, Olga, Kozlov, Viktor, Novikov, Mykola, Kosinova, Viktoriia, Oliinichenko, Olena, Kostiukova, Nina, Tkachenko, Oksana, Karnabeda, Oksana, Stratienko, Viktoriya, Kriachok, Iryna
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2018-99-118397

Introduction.PET-CT is the new imaging modality for staging of patients with Hodgkin Lymphoma (HL) with its excellent results in prognostic role for survival rate. Despite this fact, there are still patients in different risk groups who need intensification in treatment or dose de-escalation. In recent years several studies have been activated and published data about baseline, interim (iPET) and end-of-treatment (PET3) PET-CT prognostic role. But somewhere, there are still a lot of controversies. Here we report the results of a multicenter prospective study of iPET and PET3 in HL. Methods.113 patients with the primary HL were evaluated in the study. Between 113 patients 67.2% (76) were females and 32.8% (37) - males, with median age 42.5 years (range - 18 to 67years ). Patients received standart chemotherapy protocols based on risk group - ABVD or BEACOPP-14/esc. Metabolic PET-CT imaging was performed at participating PET centers according to routine protocols. iPET and PET3 with 1-3 and 4-5 scores by Deauville were considered as astatus-negative and status-positive result, respectively.The primary endpoints of the study were evaluated predicting treatment outcome and event free survival (EFS). Results.40.7% (46/113) with early stages were treated by ABVD and 59.3% (67/113) patients with advance stages received BEACOPP-esc/14 and ABVD, respectively (p